UA-026

Primary objectives: To evaluate the safety and tolerability of UA026 tablets after single and multiple oral administration in healthy adult subjects; To evaluate the safety and tolerability of UA026 tablets after oral administration in adult patients with moderate to severe psoriasis. Secondary objectives: To evaluate the pharmacokinetic characteristics of UA026 tablets after single and multiple oral administration in healthy adult subjects; To evaluate the pharmacokinetic characteristics of UA026 tablets after oral administration in adult patients with moderate to severe psoriasis; To evaluate the effect of food on the pharmacokinetics of the drug after single administration of UA026 tablets on an empty stomach and after meals in healthy adult subjects; To evaluate the preliminary efficacy of UA026 in adult patients with moderate to severe psoriasis; To evaluate the changes in pharmacodynamic biomarkers of UA026 in healthy adult subjects and adult patients with moderate to severe psoriasis. Exploratory objectives: To explore the changes in QT/QTc interval after oral administration of UA026 tablets in healthy adult subjects.